Biotech News
Related news
XENEXenon2026-11-03 21:01 EST
Xenon to Present at Upcoming Investor Conferences
XENEXenon2026-11-02 21:02 EST
Xenon to Report Q3 2026 Financial Results on November 9, 2026
PRAXPraxis Precision Medicines2026-11-04 21:01 EST
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ANNXAnnexon, Inc.2026-10-16 21:35 EST
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
XERSXeris Pharmaceuticals2026-10-02 21:00 EST
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IKTInhibikase Therapeutics2026-10-02 20:01 EST
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TSHATaysha Gene Therapies2026-11-06 13:00 EST
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TNXPTonix Pharmaceuticals2026-11-04 12:00 EST
Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference
TNXPTonix Pharmaceuticals2026-11-02 12:00 EST
Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation
ABOSAcumen Pharmaceuticals2026-10-30 11:00 EST
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint
Xenon
Ion-Channel Therapeutics Xenon Pharmaceuticals develops medicines that modulate neuronal ion channels. Its pipeline addresses epilepsy, depression and pain through mechanisms intended to control abnormal electrical signaling. Azetukalner Azetukalner is a selective Kv7 potassium-channel opener intended to reduce excessive neuronal firing....
Recent company news
XENEXenon2026-11-03 21:01 EST
Xenon to Present at Upcoming Investor Conferences
XENEXenon2026-11-02 21:02 EST
Xenon to Report Q3 2026 Financial Results on November 9, 2026
XENEXenon2026-10-30 20:01 EST
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
XENEXenon2026-10-29 12:30 EST
Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
XENEXenon2026-10-02 20:01 EST
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stock data
- Close
- 37.68 USD
- Market cap
- 5.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States